ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Persistence With Human Immunodeficiency Virus Pre-exposure Prophylaxis in the United States, 2012-2017.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06072443 (AURORA Study-A Transformative Approach Utilizing Behavioral Economics, Education, and Data Science to Support Patients Initiating PrEP With Retention-in-care and Medication Persistence), which is not on this map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
AURORA Study-A Transformative Approach Utilizing Behavioral Economics, Education, and Data Science to Support Patients Initiating PrEP With Retention-in-care and Medication Persistence
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis - United States, 2025.MMWR. Morbidity and mortality weekly report · 2025Guideline
- Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women.AIDS patient care and STDs · 2022Trial
- Persistence on Oral HIV Pre-Exposure Prophylaxis Among Key Populations at a Centre in Buenos Aires: A Survival Analysis of a Real-World Cohort.Journal of the International AIDS Society · 2026Article
- HIV Pre-exposure Prophylaxis at a Local Public Health Department in the Southern United States: Reducing Barriers, Increasing Access, and Lessons Learned.AIDS and behavior · 2026Article
- Defining HIV Pre-Exposure Prophylaxis (PrEP) Persistence: A Scoping Review.Journal of the International AIDS Society · 2026Article
- HIV Pre-Exposure Prophylaxis Service Cascade and Risk Factors Associated with Loss to Follow-Up Among Key Populations in Indonesia: Data from a Real-World Pilot Implementation 2021-2023.AIDS and behavior · 2026Article
- Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Role of pharmacists in HIV prophylaxis: a scoping review of pharmacists' services, interventions and outcomes.Journal of the International AIDS Society · 2026Article
- Assessing Non-Oral PrEP Alternatives Among Young Black Women in the Southern USA.Journal of racial and ethnic health disparities · 2026Article
- PrEParing for Long-acting Technologies: A Multistate Analysis of PrEP Persistence and HIV and STI Lab Coverage Among Oral PrEP Initiators in St. Louis, Missouri (2014-2021).Open forum infectious diseases · 2026Article
- National Trends in HIV Pre-Exposure Prophylaxis Dispensing to Young Adults, 2016-2023.Journal of general internal medicine · 2026Article
- HIV Diagnosis and Preexposure Prophylaxis (PrEP) Prescription Among Commercially Insured Persons With Bipolar Disorder.The Journal of clinical psychiatry · 2025Article
- Laser hair removal to antiretrovirals: findings from a person-centred care model for transgender people in India.Journal of the International AIDS Society · 2025Article
- A Competing Risks Duration Model to Study PrEP Discontinuation Among MSM in France: The ERAS 2023 Study.AIDS and behavior · 2025Article
- Inequities in PrEP annualized pill-day coverage, United States, 2018-2022: a cross-sectional pharmacoequity analysis.Journal of the International AIDS Society · 2025Article
- Preventing Premature Pre-Exposure Prophylaxis Discontinuation and Sexually Transmitted Infections Among Men Who Have Sex With Men (Project PEACH): Protocol for a Prospective Cohort Study.JMIR research protocols · 2025Article
- Trimethoprim sulfamethoxazole prophylaxis and serious infections in granulomatosis with polyangiitis treated with rituximab.Rheumatology (Oxford, England) · 2025Article
- County-Level Factors Associated with Reversal of Insurer-Approved HIV Pre-Exposure Prophylaxis Prescriptions in the United States, 2018.AIDS and behavior · 2025Article
- "Not Today": Overcoming PrEP Hesitancy, Stigma, and Adherence Barriers With Lenacapavir.Ochsner journal · 2025Article
- Pre-exposure prophylaxis persistence at two sites in an integrated primary health care programme in South Africa.Frontiers in public health · 2025Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDaily oral pre-exposure prophylaxis (PrEP) is highly effective in preventing human immunodeficiency virus (HIV) infection if used adherently throughout periods of HIV risk. We estimated PrEP persistence among cohorts of persons with commercial or Medicaid insurance.
methodsWe analyzed data from the IBM MarketScan Research Database to identify persons aged 18-64 years who initiated PrEP between 2012 and 2017. We assessed PrEP persistence by calculating the time period that each person continued filling PrEP prescriptions until there was a gap in prescription fills > 30 days. We used Kaplan-Meier time-to-event methods to estimate the proportion of PrEP users who persisted with PrEP at 3, 6, and 12 months after initiation, and constructed Cox proportional hazards models to determine patient characteristics associated with nonpersistence.
resultsWe studied 11 807 commercially insured and 647 Medicaid insured persons with PrEP prescriptions. Commercially insured patients persisted for a median time of 13.7 months (95% confidence interval [CI], 13.3-14.1), compared to 6.8 months (95% CI, 6.1-7.6) among Medicaid patients. Additionally, female sex, younger age, residence in rural location, and black race were associated with shorter persistence. After adjusting for covariates, we found that female sex (hazard ratio [HR], 1.81 [95% CI, 1.56-2.11]) and younger age (18-24 years: HR, 2.38 [95% CI, 2.11-2.69]) predicted nonpersistence.
conclusionsMore than half of commercially insured persons who initiated PrEP persisted with it for 12 months, compared to a third of those with Medicaid. A better understanding of reasons for nonpersistence is important to support persistent PrEP use and to develop interventions designed for the diverse needs of at-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.